China Should Focus On APIs And Pharmaceutical Preparations - CPEA Chairman
This article was originally published in PharmAsia News
The China Pharmaceutical Enterprises Association's Chairman Yu Mingde remarked that China's pharmaceutical industry should focus on developing both APIs and pharmaceutical preparations
You may also be interested in...
SHANGHAI - The Chinese government will spend RMB 5 billion ($760 million) to upgrade drug manufacturing quality assurance in an effort to help active pharmaceutical ingredient makers comply with global good manufacturing practices so they can export to the U.S. and Europe, an unnamed government official told the Shanghai Securities News
A WHO recommendation to explicitly exempt low-THC CBD from international narcotics controls has been emphatically rejected by UN member states. The CBD industry had hoped for a positive outcome to remove regulatory pressure on product manufacturers in Europe and around the world.
After its historic first emergency approval, analysts at Bernstein has upgraded predictions for Pfizer/BioNTech's COVID-19 vaccine in 2021 and beyond.